Treatment of multiple sclerosis with interferon β

Biomedicine and Pharmacotherapy

Volumn 53, Issue 8, 1999, Pages 344-350

  Arnason, B G W ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Immunomodulatory therapy; Interferon ; Multiple sclerosis

Indexed keywords

BETA1A INTERFERON; CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; INTERFERON BETA SERINE; NITRIC OXIDE SYNTHASE; RECOMBINANT BETA INTERFERON;

CLINICAL TRIAL; DISABILITY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FLU LIKE SYNDROME; HUMAN; IMMUNOMODULATION; INTRAMUSCULAR DRUG ADMINISTRATION; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REMISSION; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; WHITE MATTER;

EID: 0033197503     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0753-3322(99)80105-X     Document Type: Article

References (18)

1. IFNβ Multiple Sclerosis Study Group, University of British Columbia MS/MRI Analysis Group. Interferon β-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multi-center, randomized, double-blind, placebo-controlled trial. Neurology 1993 ; 43 : 655-61.
2. IFNβ Multiple Sclerosis Study Group, University of British Columbia MS/MRI Analysis Group. Interferon β-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. Neurology 1995 ; 44 : 1277-85.
3. Paty DW, Li DK, University of British Columbia MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Interferon β-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993 ; 43 : 662-7.
4. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Kichert JR, Salazar AM, et al. Intramuscular interferon β-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996 ; 39 : 285-94.
5. The PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised, double-blind, placebo-controlled study of interferon β-1a in relapsing-remitting multiple sclerosis: Clinical results. Lancet 1998 ; 352 : 1498-504.
6. European Study Group on Interferon β-1b in secondary Progressive Multiple Sclerosis. Placebo-controlled multicentre randomized trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998 ; 352 : 1491-7.
7. Kurtzke JF. Rating neurological impairment in multiple sclerosis. An Expanded Disability Status Scale (EDSS). Neurology 1983 ; 33 : 1444-52.
8. Stone LA, Frank JA, Albert PS, Bash C, Smith ME, Maloni H, et al. The effect of interferon β on blood brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol 1995 ; 37 : 611-9.
9. Freedman MS for the OWIMS Study Group. Dose dependent clinical and magnetic resonance imaging efficacy of interferon β-1a (Rebif®) in multiple sclerosis. Ann Neurol 1998 ; 44 : 992.
10. Pozzilli C, Bastianello S, Koudriavtseva T, Gasperini C, Bozzao A, Millefiorini E, et al. Magnetic resonance imaging changes with recombinant interferon β-1a: A short term study in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 1996 ; 61 : 251-8.
11. Munafo A, Trinchard-Lugan I, Nguyen TXQ, Buraglio M. Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon β-1a after intramuscular and subcutaneous administration. Euro J Neurol 1998 ; 5 : 187-93.
12. Rudick R, Fisher E, Lee J, Simon J, Miller D, Jacobs L, et al. The effect of Avonex® (IFN β-1a) on cerebral atrophy in relapsing multiple sclerosis. Neurology 1998 ; 52 Suppl : 289-90.
13. Arnason BG, Dianzani F. Correlation of the appearance of anti-interferon antibodies during treatment and diminution of efficacy: Summary of an international workshop on anti-interferon antibodies. J Interferon Cytokine Res 1998 ; 18 : 639-44.
14. Arnason BGW, Dayal A, Xiang Qu Z, Jensen MA, Genc K, Reder AT. Mechanisms of action of interferon β in multiple sclerosis. Springer Semin Immunopathol 1996 ; 18 : 125-48.
15. Pozzilli C, Passafiume D, Bernardi S, Pantano P, Incoccia C, Bastianello S, et al. SPECT, MRI and cognitive function in multiple sclerosis. J Neurolog Neurosurgery Psychiatry 1991 ; 54 : 110-5.
16. Narayanan S, Stefano ND, Francis GS, Arnaoutelis R, Pelletier D, Caramanos Z, et al. Restoration of Cerebral Axonal Function in Multiple Sclerosis Patients Treated with Interferon β-1b. Submitted.
17. Pliskin NH, Hamer DP, Goldstein DS, Towle VL, Reder AT, Noronha A, et al. Improved neuropsychological function in multiple sclerosis patients receiving Interferon β-1b. Neurology 1996 ; 47 : 1463-8.
18. Broderick CF, Hsu LM, Massoth NA. Neuropsychological performance of MS patients with and without the use of Avonex® (interferon β-1a). Neurology 1999 ; 52 Suppl 2 : 499-500.